FTC Concerns Over Bristol-Myers Deal Raise Questions
On Jan. 3, 2019, Bristol-Myers Squibb Co. announced its proposed acquisition of Celgene Corp. for approximately $74 billion. The Federal Trade Commission issued requests for additional information and documentary materials to...To view the full article, register now.
Already a subscriber? Click here to view full article